Skip to main content
Kangmei Pharmaceutical Co.,Ltd logo

Kangmei Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 600518 ISIN · CNE0000017M1 LEI · 3003006FRNBUUTVKBB50 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,368 across all filing types
Latest filing 2026-05-14 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600518

About Kangmei Pharmaceutical Co.,Ltd

http://www.kangmei.com.cn

Kangmei Pharmaceutical Co.,Ltd. focuses on the research, development, production, and distribution of Traditional Chinese Medicine (TCM). The company manages an integrated industry chain that includes herbal cultivation, standardized processing of decoction pieces, and the manufacturing of patent medicines. Its offerings extend to health supplements, medical devices, and functional foods. A key component of its operations is the management of large-scale TCM trading centers and logistics hubs designed to standardize the trade of medicinal materials. Through its "Internet + Healthcare" initiatives, the company provides digital health management and pharmaceutical supply chain services, catering to medical institutions, retail pharmacies, and individual consumers.

Recent filings

Filing Released Lang Actions
广东信达律师事务所关于康美药业股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a formal legal opinion letter from Guangdong Sundial Law Firm regarding the 2025 Annual General Meeting of Kangmei Pharmaceutical. Although it contains legal attestations, its core content is the detailed listing of shareholder vote results on each AGM resolution. Under our taxonomy, documents that report official voting outcomes at a general meeting are classified as Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-14 Chinese
康美药业关于召开2025年度暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 80% confidence The document is a Chinese regulatory announcement by Kangmei Pharmaceuticals about convening a performance briefing (“业绩说明会”) for its 2025 annual and 2026 Q1 results. It is not the actual financial report or earnings release, nor is it a proxy/material for voting, nor a transcript. It simply provides logistical details for an investor meeting. This falls into the fallback “Regulatory Filings (RNS)” category for miscellaneous regulatory notices that don’t fit other specific types.
2026-05-14 Chinese
康美药业关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a formal notice of the company’s 2025 Annual General Meeting, outlining meeting date, location, agenda items for shareholder approval, voting procedures, and including a proxy form. It is clearly a solicitation of proxies and information statement sent to shareholders to request votes. Therefore, it falls under Proxy Solicitation & Information Statement.
2026-04-17 Chinese
康美药业关于2025年度拟不进行利润分配的公告
Notice of Dividend Amount Classification · 85% confidence The document is a formal announcement by the board regarding the company’s profit distribution plan for 2025, explicitly stating no dividend or capital reserve transfer will be made and providing details of the decision process. It falls squarely under announcements about dividend distributions (even though it is a ‘no distribution’ notice), matching the “Notice of Dividend Amount” category (DIV).
2026-04-17 Chinese
康美药业关于董事、高级管理人员2026年度薪酬方案的公告
Remuneration Information Classification · 88% confidence The document is an announcement entitled “关于董事、高级管理人员2026年度薪酬方案的公告,” outlining the detailed compensation scheme for company directors and senior management for fiscal year 2026. It is not reporting a change in personnel, nor announcing an upcoming report, but rather specifying remuneration policy. This matches the definition of Remuneration Information (Code: DEF 14A).
2026-04-17 Chinese
康美药业2025年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '康美药业股份有限公司2025年年度报告摘要' (Kangmei Pharmaceutical Co., Ltd. 2025 Annual Report Summary). It contains key financial data, business descriptions, and shareholder information for the fiscal year 2025. While it is a summary, it serves as the official disclosure of the annual financial performance and is distinct from a mere announcement of a report's availability. In the context of Chinese A-share filings, the 'Annual Report Summary' (年度报告摘要) is a standard component of the full Annual Report (10-K equivalent) and contains substantive financial data, thus it is classified as an Annual Report. FY 2025
2026-04-17 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.